Cadrenal Therapeutics Q1 EPS $(0.10) Misses $(0.07) Estimate
Portfolio Pulse from Benzinga Newsdesk
Cadrenal Therapeutics (NASDAQ:CVKD) reported Q1 EPS of $(0.10), missing the consensus estimate of $(0.07) by 42.86%. This represents a 79.17% improvement over the $(0.48) per share loss from the same period last year.
May 09, 2024 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Cadrenal Therapeutics reported a Q1 EPS of $(0.10), missing estimates but showing significant year-over-year improvement.
While Cadrenal Therapeutics missed the EPS estimate, the significant improvement from the previous year's loss indicates a positive trend in reducing losses. This mixed result could lead to neutral short-term stock price movement as investors weigh the missed expectations against the year-over-year improvement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100